APA (7th ed.) Citation

AJ, M. L., K, E., H, W., L, P., C, P., K, S., . . . WG, P. (2025). SARS-CoV-2 N protein and anti-spike serologies: Insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial. Therapeutic advances in infectious disease, 12, 20499361251333617. https://doi.org/10.1177/20499361251333617

Chicago Style (17th ed.) Citation

AJ, Mena Lora, et al. "SARS-CoV-2 N Protein and Anti-spike Serologies: Insights into COVID-19 Disease Severity and Mortality-a Secondary Analysis of the ACTIV-1 Trial." Therapeutic Advances in Infectious Disease 12 (2025): 20499361251333617. https://doi.org/10.1177/20499361251333617.

MLA (9th ed.) Citation

AJ, Mena Lora, et al. "SARS-CoV-2 N Protein and Anti-spike Serologies: Insights into COVID-19 Disease Severity and Mortality-a Secondary Analysis of the ACTIV-1 Trial." Therapeutic Advances in Infectious Disease, vol. 12, 2025, p. 20499361251333617, https://doi.org/10.1177/20499361251333617.